FDA approves Gilead cancer gene therapy; price set at $373000 – Reuters
|
FDA approves Gilead cancer gene therapy; price set at $373000
Reuters (Reuters) – U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's (GILD.O) Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. |
